Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17988200 | 0.92 | KDM1A (0.44) | KDM1ANFKB1NFKB2RELAALOX15 | |
| SCHEMBL17988166 | 0.90 | KDM1A (0.55) | KDM1ANFKB1NFKB2RELA | |
| SCHEMBL17988049 | 0.89 | KDM1A (0.57) | KDM1ANFKB1NFKB2RELAOPRD1 | |
| SCHEMBL17988198 | 0.84 | KDM1A (0.49) | KDM1A | |
| SCHEMBL17988194 | 0.84 | KDM1A (0.49) | KDM1AMAOAMAOB | |
| SCHEMBL17988106 | 0.84 | KDM1A (0.49) | KDM1ANFKB1NFKB2RELA | |
| SCHEMBL25069709 | 0.82 | KDM1A (0.54) | KDM1AMAOAMAOB | |
| SCHEMBL25069745 | 0.82 | KDM1A (0.54) | KDM1AMAOAMAOB | |
| SCHEMBL17988169 | 0.82 | KDM1A (0.51) | KDM1ANFKB1NFKB2RELA | |
| SCHEMBL17988165 | 0.81 | KDM1A (0.51) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301253-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3250552-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3250552-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016123387-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123387-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301253-B2 | Therapeutic compounds and uses thereof | KDM1B, HDAC1, DOT1L | KDM1A 7/4885NFKB1 1654/4885NFKB2 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.